Cumberland Pharmaceuticals’ Ifetroban Secures the US FDA’s ODD and RPDD for Duchenne Muscular Dystrophy
Shots:
- The US FDA has granted ODD & RPDD to ifetroban for treating cardiomyopathy related to Duchenne muscular dystrophy (DMD)
- Ifetroban (QD, oral) is a selective thromboxane-prostanoid receptor (TPr) antagonist being investigated under P-II (FIGHT DMD) study for its safety, efficacy & PK in DMD patients, with results anticipated during Q4’24
- The company is also conducting another P-II (FIGHTING FIBROSIS) study for assessing the safety & efficacy of ifetroban vs PBO in patients with idiopathic pulmonary fibrosis (IPF) for over 52wks.
Ref: Cumberland Pharmaceuticals | Image: Cumberland Pharmaceuticals
Related News:- Shorla Oncology Reports the US FDA’s Expanded Approval of Jylamvo for Pediatric Indications
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
A passionate content writer with expertise in delivering high-quality and engaging content, Dipanshu is a keen reader and a versatile writer. Dipanshu dedicatedly covers news ranging from biopharma, life sciences, biotech, and MedTech to diagnostics and animal health companies. He can be contacted at connect@pharmashots.com
